Get access to our best features
Get Started
Subscribe
Israel-Hamas Conflict
Donald Trump
Kamala Harris
Volleyball
US Open
NFL
US Economy
US Politics
Soccer
Republican Party
US Crime
US Immigration
School Shooting
Get access to our best features
Get Started
Published

La EMA desaconseja autorizar en la UE el lecanemab, un fármaco contra los síntomas del alzhéimer

Summary by Eldiario.es
The medicine, with the brand name Leqembi, raises concerns for the possibility of causing inflammation and bleeding in the brain

0 Articles

All
Left
Center
Right
Eldiario.esEldiario.es

La EMA desaconseja autorizar en la UE el lecanemab, un fármaco contra los síntomas del alzhéimer

The medicine, with the brand name Leqembi, raises concerns for the possibility of causing inflammation and bleeding in the brain

·Spain
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

SpainSpain

You have read 0 out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal